Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform. Mindleap™ is working towards contributing to the evolution of…
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company"), is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company's new Chief Marketing Officer ("CMO"). "When I was first contacted by Damon Michaels, the company's Chief Operations Officer,…
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in…
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board. Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last…
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: MYCOF) is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee. The new members of the science team will provide scientific expertise and corporate strategy support as Mydecine begins its R&D program at its Innovation Center in Denver,…
Mydecine Innovations Group Inc. (CNSX: MYCO) (OTCMKTS: MYCOF) is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. for the acquisition of a 100% interest in MindLeap’s Digital Telehealth Platform focused on the emerging psychedelics industry. Pursuant to the share exchange agreement, Mydecine…
